Get Access to Fosdenopterin for injection in India        

Nulibry is cyclic pyranopterin monophosphate (cPMP) used to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

Recommended Dosage: Start therapy with Nulibry injection if the patient has a diagnosis or presumptive diagnosis of molybdenum cofactor deficiency Type A. In patients with a presumptive diagnosis of molybdenum cofactor deficiency Type A, confirm the diagnosis of molybdenum cofactor deficiency Type A promptly after starting Nulibry therapy. In such patients, discontinue this treatment if the MoCD Type A diagnosis is not confirmed by genetic testing.

Nulibry medicine is intended for administration by a health specialist. In case deemed apt by a health specialist, this medicine may be given at home by the patient’s caregiver. The drug is for intravenous infusion only. Use with non-DEHP tubing with a 0.2 micron filter. Avoid mixing this medicine (Nulibry) with other medicinal products. Avoid administering as an infusion with other drugs.

Recommended Dosage for Patients One Year of Age or Older: For patients 1 year of age or older, the recommended dosage is fosdenopterin 9.5 mg/kg (based on actual body weight) administered as an intravenous infusion once daily.

If a dose of Nulibry is missed, administer the missed/skipped dose as promptly as possible. Administer the very next scheduled dose at least six hours after the administration of the missed/skipped dose.